Literature DB >> 3882114

A preliminary trial of a novel form of active immunotherapy in squamous cell carcinoma of the lung.

P J Lachmann, R M Grant, L S Freedman, K Sikora, N M Bleehen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 3882114      PMCID： PMC1976946          DOI： 10.1038/bjc.1985.56

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  6 in total

1.  The heterogenization of tumour cells with tuberculin. I. The coupling of tuberculin to cell surfaces using con-A as ligand.

Authors:  P J Lachmann; A Vyakarnam; K Sikora
Journal:  Immunology       Date:  1981-02       Impact factor: 7.397

2.  Specific antigens on methylcholanthrene-induced tumors of mice.

Authors:  E S Lennox; A D Lowe; J Cohn; G Evan
Journal:  Transplant Proc       Date:  1981-12       Impact factor: 1.066

3.  Estimation of the proportional hazard in two-treatment-group clinical trials.

Authors:  L Bernstein; J Anderson; M C Pike
Journal:  Biometrics       Date:  1981-09       Impact factor: 2.571

4.  The heterogenization of tumour cells with tuberculin. II. Studies of the antigenicity of tuberculin-heterogenized murine tumour cells in syngeneic BCG positive and BCG negative mice.

Authors:  A Vyakarnam; P J Lachmann; K Sikora
Journal:  Immunology       Date:  1981-02       Impact factor: 7.397

5.  Studies in the enhancement of tumour immunity by coupling strong antigens to tumour cells ('heterogenization of tumours'). Helper T cell clones against PPD help other T cells mount anti-tumour responses to PPD-coupled tumour cells.

Authors:  D Y Sia; P J Lachmann; K N Leung
Journal:  Immunology       Date:  1984-04       Impact factor: 7.397

6.  Viral oncolysis: increased immunogenicity of host cell antigen associated with influenza virus.

Authors:  J Lindenmann; P A Klein
Journal:  J Exp Med       Date:  1967-07-01       Impact factor: 14.307
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.